With a strategy of outsourcing research and out-licensing drug candidates early, ValiRx aims to sidestep potential costly clinical trial failures. We expect ValiRx to deliver its first clinical trial readout in Q1-2016: namely that of its most advanced development product, VAL201, a treatment for prostate cancer.
14 Oct 2015
Lower risk drug development model
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Lower risk drug development model
ValiRx PLC (VAL:LON) | 3.4 0 0.0% | Mkt Cap: 4.57m
- Published:
14 Oct 2015 -
Author:
Vadim Alexandre -
Pages:
20
With a strategy of outsourcing research and out-licensing drug candidates early, ValiRx aims to sidestep potential costly clinical trial failures. We expect ValiRx to deliver its first clinical trial readout in Q1-2016: namely that of its most advanced development product, VAL201, a treatment for prostate cancer.